Congo poised to mobilise diagnostics in face of "high-mortality unknown illness":
This article was originally published in Clinica
Executive Summary
International epidemiology experts are awaiting the results of laboratory tests on samples related to an "unknown high-mortality" disease in the Democratic Republic of Congo. Healthcare and surveillance teams from the health ministry and the Institut National de Recherches Biologiques, backed by the WHO, are investigating the situation, which is centred in Kasai Occidental province. The exact number of cases and deaths is not yet known, according to a WHO notice, dated August 31, but the majority involves infants under the age of 10, presenting with fever, headache, diarrhoea/abdominal pain and vomiting. The Global Outbreak Alert and Response Network (GOARN) and the WHO are supporting the government's epidemiological investigations and logistics efforts.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.